Evidence map›Paper›PMID 41763101›Full record

ArticleThe journal of prevention of Alzheimer's disease2026

Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies.

Marc W Haut, Camila Vieira Ligo Teixeira, Patrick D Worhunsky, Rashi I Mehta, Joseph E Malone, Melanie Ward, Cierra M Keith, Holly E Phelps, Stephanie Pockl, Nafiisah Rajabalee and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marc W HautRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Behavioral Medicine and Psychiatry, Morgantown, USA; Department of Neurology, Morgantown, USA. Electronic address: mhaut@hsc.wvu.edu.
Camila Vieira Ligo TeixeiraRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA.
Patrick D WorhunskyRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA.
Rashi I MehtaRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neuroradiology, Morgantown, USA.
Joseph E MaloneRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neurology, Morgantown, USA.
Melanie WardRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neurology, Morgantown, USA.
Cierra M KeithRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Behavioral Medicine and Psychiatry, Morgantown, USA.
Holly E PhelpsRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Behavioral Medicine and Psychiatry, Morgantown, USA.
Stephanie PocklRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Medicine, Morgantown, USA.
Nafiisah RajabaleeRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Medicine, Morgantown, USA.
Khalid SharifRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Behavioral Medicine and Psychiatry, Morgantown, USA.
Gary MaranoRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neuroradiology, Morgantown, USA.
Pierre-Francois D'HaeseRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neuroradiology, Morgantown, USA.
Ali R RezaiRockefeller Neuroscience Institute West Virginia University, Morgantown, West Virginia, USA; Department of Neurosurgery, Morgantown, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid related imaging abnormalities (ARIA) are the most significant risk associated with the use of anti-amyloid monoclonal antibodies (MAB) for Alzheimer's disease (AD). Currently, the presence of the APOE ε4 allele is the best predictor for the development of ARIA. However, the degree of baseline memory impairment has not been fully explored as a risk factor for ARIA. Here, we examined MAB outcomes in a memory clinic population and compared patients with AD who developed ARIA to a case-matched group who did not develop ARIA. Participants who developed ARIA had greater numbers of recall intrusions and false positives, both markers for memory consolidation, at baseline than those who did not develop ARIA. We also observed greater baseline hippocampal and supplementary motor cortical atrophy with ARIA. These differences remained when controlling for the APOE ε4 allele and the presence of pretreatment microhemorrhages. Further investigation of memory impairment and associated brain atrophy is warranted to understand ARIA risk and MAB outcomes in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalMemory ConsolidationMemory DisordersAgedApolipoprotein E4AtrophyBrainCase-Control StudiesFemaleHumansMagnetic Resonance ImagingMaleAmyloid beta-PeptidesAntibodies, MonoclonalApolipoprotein E4Alzheimer'sARIAMemory consolidationMonoclonal antibodies

Identifiers

PMID41763101
PMCPMC12966669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.